Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 20/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 19/20 | 1.00 |
| ▸ | FLT1 | P17948 | 5/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906674 | 1.00 | EPHA2 (1.00) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL1791467 | 1.00 | EPHA2 (1.00) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL1791469 | 1.00 | EPHA2 (1.00) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL906644 | 1.00 | EPHA2 (1.00) | EPHA2KDREPHB4ERBB2FLT1 | |
| Hydrochloric Acid SCHEMBL906859 | 0.99 | EPHA2 (0.98) | EPHA2KDREPHB4ERBB2FLT1 | |
| Hydrochloric Acid SCHEMBL906860 | 0.99 | EPHA2 (0.98) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL13590379 | 0.93 | ERBB2 (0.87) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL12942155 | 0.93 | ERBB2 (0.87) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL1789690 | 0.93 | ERBB2 (1.00) | EPHA2KDREPHB4ERBB2FLT1 | |
| SCHEMBL1793449 | 0.93 | ERBB2 (1.00) | EPHA2KDREPHB4ERBB2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | claimed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8658654-B2 | Receptor-type kinase modulators and methods of use | SYMPHONY EVOLUTION, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2277867-B1 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | SYMPHONY EVOLUTION INC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | EPHA2 4/4885KDR 16/4885EPHB4 17/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | EPHA2 2745/4885KDR 2390/4885EPHB4 2878/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | EPHA2 2557/4885KDR 3082/4885EPHB4 2530/4885 |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | EPHA2 977/4885KDR 1023/4885EPHB4 1441/4885 |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.